This morning, Bristol-Myers Squibb Company (BMY) reported third quarter earnings of 52 cents per share, beating the Zacks Consensus Estimate by a penny. The company reported earnings of 45 cents in the year-ago period.
Net sales for the quarter came in at $5,487 million, against $5,254 million in the year-ago quarter, thus representing an increase of 4.4%. It comprised $4,788 million in pharmaceutical product sales, up 6%, and $699 million in Nutritional sales, down 6%.
Growth in the pharmaceutical division was driven by strong sales of Plavix at $1,554 million, up 8%, HIV medication Sustiva at $315 million, up 7% and hepatitis B drug Baraclude at $191 million, up 33%, Schizophrenia drug Abilify came in at $653 million, up 16%, rheumatoid arthritis drug Orencia was at $162 million, up 36% and leukemia drug Sprycel reached $107 million, up 30%.
However, cancer drug Erbitux generated sales of $179 million in the second quarter, a decrease of 3%. Furthermore, Onglyza, co-developed with AstraZeneca plc (AZN), was recently launched in the US as well as Europe for type-II diabetes. The drug recorded sales of approximately $20 million in the quarter.
Marketing, selling and administrative expenses decreased 8% to $1,117 million in the third quarter of 2009, primarily because of a continued reduction in general and administrative expenses. Advertising and product promotion spending was flat at $361 million in the third quarter of 2009. Research and development expenses came in at $838 million compared to $834 million in the third quarter of 2008.
Bristol exited the quarter with cash, cash equivalents and marketable securities of $7.9 billion. The company expects to end the year with earnings between $2.00 and $2.05 which implies growth of a minimum of 15%. Revenue is expected to grow in the mid-single digits which includes a significant foreign exchange headwind.
During the quarter, Bristol-Myers completed the acquisition of Medarex Inc. for $2.1 billion. Through this acquisition it strengthens its product portfolio since the company has acquired the UltiMAb Human Antibody Development System, which produces high-affinity, fully human antibodies for use in a broad range of therapeutic areas, including immunology and oncology.
Bristol-Myers also gets access to Medarex’s next-generation Antibody-Drug Conjugate (ADC) technology, which is a novel and proprietary platform that could open new fields in oncology drug development.
Furhermore, Bristol-Myers has acquired full ownership rights to ipilimumab, which was being developed jointly with Medarex. Ipilimumab, which is in late-stage clinical testing, could be a significant contributor to the company’s future growth on approval.
The acquisition of Medarex is aimed to counter the loss of revenues that will arise once Bristol-Myers loses exclusivity on its key product Plavix, co-promoted with Sanofi-Aventis (SNY), in 2011.
Moreover, Plavix is facing competition from Eli Lilly’s (LLY) Effient which was launched recently. Additionally, Bristol is working to build a strong pipeline of candidates that could contribute to revenues in the coming years. Furthermore, Bristol’s management is aiming to reduce costs and is shedding less profitable and non-core businesses.
Read the full analyst report on “BMY”
Read the full analyst report on “AZN”
Read the full analyst report on “SNY”
Read the full analyst report on “LLY”
Zacks Investment Research
